Gene · 10516
Papers1,386
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,386
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Statement of Retraction: Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5). | Bioengineered | 2026 | 42821366 | PubTator, text mining | PubMed |
| FGF23 blockade induces maladaptive vascular remodelling, reducing pathologically increased arterial stiffness and blood pressure. | Nephrol Dial Transplant | 2026 | 42784441 | PubTator, text mining | PubMed |
| Connective tissue and genetics in the pathogenesis of rectal prolapse: A scoping review. | Colorectal Dis | 2026 | 42765168 | PubTator, text mining | PubMed |
| Integrative transcriptomic analysis identifies ACP5 and FBLN5 as candidate shared transcriptomic signatures between pulpitis and carotid plaque rupture. | Sci Rep | 2026 | 42744917 | PubTator, text mining | PubMed |
Retraction notice to "Protein interaction network drive more group integrated analytic larynx hub protein markers: LYVE1/FBLN5/INMT/DCN/ZFY/RSPO3 protein macromolecule collaborative diagnosis of a new era" [Int. J. Biol. Macromol. 315 (2025) 144586]. | Int J Biol Macromol | 2026 | 42552209 | PubTator, text mining | PubMed |
| miR-1911-3p Regulates Malignant Biological Behaviors and Glycolytic Activity of Triple-Negative Breast Cancer via FBLN5. | Breast Cancer (Dove Med Press) | 2026 | 42517063 | PubTator, text mining | PubMed |
| Late-Onset Preeclampsia Is Linked to Extensive Remodeling of the Placental Extracellular Matrix. | Med Sci (Basel) | 2026 | 42506333 | PubTator, text mining | PubMed |
| Genetic susceptibility to obesity-related asthma and its modulation by sequelae of obesity. | bioRxiv | 2026 | 42395418 | PubTator, text mining | PubMed |
| Identification of fibulin-5 as a granzyme B substrate involved in UVB-induced elastic fiber disruption. | J Invest Dermatol | 2026 | 42331310 | PubTator, text mining | PubMed |
| Exploring hypoxia-related genes as prognostic indicators in lung adenocarcinoma. | PLoS One | 2026 | 42234659 | PubTator, text mining | PubMed |
| Fibulin-5 (FBLN5) as a context-dependent pan-cancer regulator: integrated multi-omics analysis reveals dual roles in tumor progression and therapeutic resistance. | Transl Cancer Res | 2026 | 42180915 | PubTator, text mining | PubMed |
| Endothelial-derived PANoptosis factor IL33 is a potential immunotherapy in breast cancer. | iScience | 2026 | 42095097 | PubTator, text mining | PubMed |
| Engineered natural extracellular matrix platform for modelling skin diseases and identifying therapeutic targets. | J Adv Res | 2026 | 42082149 | PubTator, text mining | PubMed |
| Discovery and Validation of SVEP1 and Other Novel Cardiovascular Biomarkers For Patients with Kidney Failure On Maintenance Hemodialysis. | medRxiv | 2026 | 42078398 | PubTator, text mining | PubMed |
| Integrin-Binding Matricellular Protein Fibulin-5 Maintains Epidermal Stem Cell Heterogeneity During Skin Aging. | Aging Cell | 2026 | 41960991 | PubTator, text mining | PubMed |
| The mechanism of S100A4 regulating Fibulin-5 expression to promote the proliferation and migration of PASMCs. | Sleep Breath | 2026 | 41922812 | PubTator, text mining | PubMed |
| TriHex Technology and Reversal of Solar Elastosis: Dispelling Some Myths. | J Cosmet Dermatol | 2026 | 41918136 | PubTator, text mining | PubMed |
| Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma. | Int J Med Sci | 2026 | 41799774 | PubTator, text mining | PubMed |
| Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study. | J Cachexia Sarcopenia Muscle | 2026 | 41782349 | PubTator, text mining | PubMed |
| Cranial Nerve Involvement With Diplopia as Presenting Feature of CMT1H Caused by Recurring FBLN5 Variant. | J Peripher Nerv Syst | 2026 | 41782179 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10516/papers